Drug class
Farnesoid X Receptor (FXR) Agonists, Bile Acid Analogs
Farnesoid X receptor agonists that are bile acid analogs represent a specialized class of semi-synthetic nuclear receptor ligands, exemplified clinically by obeticholic acid. Read more about Farnesoid X Receptor (FXR) Agonists, Bile Acid Analogs
0 drugs in this class 0 manufacturers
Drugs in Farnesoid X Receptor (FXR) Agonists, Bile Acid Analogs
No drugs are available
This class does not currently contain public drugs.
Farnesoid X receptor agonists that are bile acid analogs represent a specialized class of semi-synthetic nuclear receptor ligands, exemplified clinically by obeticholic acid.
These agents selectively bind to and activate the farnesoid X receptor, which downregulates endogenous hepatic bile acid synthesis, promotes bile acid transport and excretion, and mitigates cholestasis-driven hepatocellular toxicity.
Therapeutically, this pharmacologic class is utilized primarily in chronic cholestatic liver disease, specifically for managing primary biliary cholangitis in patients with inadequate response or intolerance to first-line ursodeoxycholic acid therapy.
-
fda.gov
Farnesoid X receptor agonists that are bile acid analogs represent a specialized class of semi-synthetic nuclear receptor ligands, exemplified clinically by obeticholic acid
-
rxlist.com
Farnesoid X receptor agonists that are bile acid analogs represent a specialized class of semi-synthetic nuclear receptor ligands, exemplified clinically by obeticholic acid Therapeutically, this pharmacologic class is utilized primarily in chronic cholestatic liver disease, specifically for managing primary biliary cholangitis in patients with inadequate response or intolerance to first-line ursodeoxycholic acid therapy
-
fda.gov
These agents selectively bind to and activate the farnesoid X receptor, which downregulates endogenous hepatic bile acid synthesis, promotes bile acid transport and excretion, and mitigates cholestasis-driven hepatocellular toxicity
-
amegroups.org
These agents selectively bind to and activate the farnesoid X receptor, which downregulates endogenous hepatic bile acid synthesis, promotes bile acid transport and excretion, and mitigates cholestasis-driven hepatocellular toxicity
-
fda.gov
Therapeutically, this pharmacologic class is utilized primarily in chronic cholestatic liver disease, specifically for managing primary biliary cholangitis in patients with inadequate response or intolerance to first-line ursodeoxycholic acid therapy
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.